Table 5.

Incidence and HR of cancer between subjects with and without statin among patients with interstitial lung disease and pulmonary fibrosis in non-matched cohorts using Cox proportional hazard model

Follow-up years	Statin						Crude HR (95% CI)	Adjusted HR‡ (95% CI)
	No			Yes
	Event	PY	Rate†	Event	PY	Rate†
<0.5	2331	14 544	160.3	1035	10 454	99.0	0.63 (0.58 to 0.67)***	0.56 (0.51 to 0.61)***
0.5–1	168	14 085	11.9	85	10 218	8.32	0.70 (0.54 to 0.91)**	0.46 (0.33 to 0.62)***
1–2	245	25 831	9.48	154	18 991	8.11	0.86 (0.70 to 1.05)	0.54 (0.43 to 0.70)***
2–3	212	21 936	9.66	143	16 461	8.69	0.90 (0.73 to 1.11)	0.56 (0.43 to 0.73)***
≥3	696	74 400	9.35	614	59 942	10.2	1.09 (0.98 to 1.22)	0.69 (0.60 to 0.79)***

**P<0.01, ***P<0.001.

†Rate, incidence rate, per 1000 person-years; crude HR, relative HR.

‡Adjusting for age, gender, comorbidity of sleep disorder, diabetes, hypertension, hyperlipidaemia, mental disorders, alcohol-related illness, chronic kidney disease, gout, CAD and stroke, and ICS and OS medication.

CAD, coronary artery disease; ICS, inhaled corticosteroids; OS, oral steroids; PY, person-years.